GH · Guardant Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $301.67M | - | $265.20M | $232.09M | $203.47M | - | $191.48M | $177.24M | $168.49M | - |
| Cost of Revenue | $104.92M | - | $74.49M | $81.20M | $65.30M | - | - | - | - | - |
| Gross Profit | $196.75M | - | $190.71M | $150.88M | $138.18M | - | - | - | - | - |
| R&D | $91.04M | - | $89.96M | $87.45M | $88.52M | - | $87.31M | $83.10M | $83.80M | - |
| SG&A | $57.93M | - | $53.27M | $50.26M | $46.95M | - | $49.13M | $40.46M | $38.65M | - |
| Total Operating Expenses | $423.01M | - | $364.19M | $338.50M | $314.51M | - | $308.80M | $277.85M | $268.17M | - |
| D&A | $9.44M | - | $9.00M | $9.60M | $10.24M | - | $10.10M | $10.10M | $10.71M | - |
| Operating Income | ($121.35M) | - | ($98.99M) | ($106.41M) | ($111.04M) | - | ($117.33M) | ($100.62M) | ($99.68M) | - |
| Interest Expense | $1.35M | - | $645.0K | $645.0K | $645.0K | - | $646.0K | $645.0K | $645.0K | - |
| Income Tax | $372.0K | - | $136.0K | $38.0K | $290.0K | - | $30.0K | $133.0K | $405.0K | - |
| Net Income | ($112.08M) | - | ($92.72M) | ($99.90M) | ($95.16M) | - | ($107.75M) | ($102.63M) | ($114.98M) | - |
| EPS - Basic | ($0.85) | - | ($0.74) | ($0.80) | ($0.77) | - | ($0.88) | ($0.84) | ($0.94) | - |
| EPS - Diluted | ($0.85) | - | ($0.74) | ($0.80) | ($0.77) | - | ($0.88) | ($0.84) | ($0.94) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $989.29M | $378.20M | $580.01M | $629.14M | $698.57M | $525.54M | $585.02M | $933.69M | $1.03B | $1.13B |
| Accounts Receivable | $137.40M | $137.85M | $115.58M | $130.25M | $115.43M | $110.25M | $88.47M | $100.52M | $84.56M | $88.78M |
| Inventory | $83.85M | $85.88M | $90.49M | $84.06M | $77.26M | $71.08M | $72.30M | $66.98M | $62.99M | $61.95M |
| Accounts Payable | $75.03M | $54.44M | $20.14M | $44.80M | $49.77M | $38.55M | $15.47M | $42.45M | $37.60M | $51.74M |
| Current Assets | $1.37B | $1.47B | $828.88M | $883.43M | $927.03M | $1.06B | $1.23B | $1.29B | $1.31B | $1.35B |
| Total Assets | $1.92B | $2.01B | $1.28B | $1.33B | $1.34B | $1.49B | $1.54B | $1.61B | $1.70B | $1.79B |
| Current Liabilities | $292.14M | $302.73M | $236.92M | $238.43M | $225.75M | $225.58M | $197.34M | $201.57M | $220.01M | $205.92M |
| Long-term Debt | $1.50B | $1.50B | $1.11B | $1.12B | $1.14B | - | - | - | - | - |
| Total Liabilities | $2.10B | $2.11B | $1.63B | $1.64B | $1.60B | $1.63B | $1.60B | $1.61B | $1.64B | $1.63B |
| Stockholders' Equity | ($181.07M) | ($99.31M) | ($354.47M) | ($305.48M) | ($250.79M) | ($139.65M) | ($60.10M) | ($1.61M) | $68.28M | $158.68M |
| Retained Earnings | ($3.11B) | ($2.99B) | ($2.87B) | ($2.77B) | ($2.67B) | ($2.58B) | ($2.47B) | ($2.36B) | ($2.26B) | ($2.14B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($65.62M) | - | - | - | ($62.69M) | - | - | - | ($30.28M) | - |
| Investing Cash Flow | $699.42M | - | - | - | $302.86M | - | - | - | $28.07M | - |
| Financing Cash Flow | ($21.58M) | - | - | - | ($66.85M) | - | - | - | ($1.07M) | - |
| CapEx | $5.58M | - | - | - | $4.46M | - | - | - | $6.93M | - |
| Free Cash Flow | ($71.20M) | - | - | - | ($67.15M) | - | - | - | ($37.22M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 65.2% | - | 71.9% | 65.0% | 67.9% | - | - | - | - | - |
| Operating margin | -40.2% | - | -37.3% | -45.9% | -54.6% | - | -61.3% | -56.8% | -59.2% | - |
| EBITDA margin | -37.1% | - | -33.9% | -41.7% | -49.5% | - | -56.0% | -51.1% | -52.8% | - |
| Net margin | -37.2% | - | -35.0% | -43.0% | -46.8% | - | -56.3% | -57.9% | -68.2% | - |
| Free cash flow margin | -23.6% | - | - | - | -33.0% | - | - | - | -22.1% | - |
| FCF / Net income | 0.64 | - | - | - | 0.71 | - | - | - | 0.32 | - |
| R&D / Revenue | 30.2% | - | 33.9% | 37.7% | 43.5% | - | 45.6% | 46.9% | 49.7% | - |
| SG&A / Revenue | 19.2% | - | 20.1% | 21.7% | 23.1% | - | 25.7% | 22.8% | 22.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.9% | - | -7.3% | -7.5% | -7.1% | - | -7.0% | -6.4% | -6.7% | - |
| Return on equity | 61.9% | - | 26.2% | 32.7% | 37.9% | - | 179.3% | 6362.6% | -168.4% | - |
| Return on invested capital | -7.2% | - | -10.3% | -10.4% | -9.8% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.68 | 4.84 | 3.50 | 3.71 | 4.11 | 4.68 | 6.22 | 6.40 | 5.95 | 6.54 |
| Quick ratio | 4.39 | 4.56 | 3.12 | 3.35 | 3.76 | 4.36 | 5.85 | 6.07 | 5.66 | 6.24 |
| Cash ratio | 3.39 | 1.25 | 2.45 | 2.64 | 3.09 | 2.33 | 2.96 | 4.63 | 4.68 | 5.50 |
| Leverage | ||||||||||
| Debt / Equity | -8.30 | -15.14 | -3.14 | -3.65 | -4.56 | - | - | - | - | - |
| Debt / Assets | 0.78 | 0.75 | 0.87 | 0.84 | 0.85 | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -90.1x | - | -153.5x | -165.0x | -172.2x | - | -181.6x | -156.0x | -154.5x | - |
| Equity multiplier | -10.58 | -20.28 | -3.60 | -4.36 | -5.36 | -10.64 | -25.60 | -997.73 | 24.96 | 11.26 |
| Liabilities / Assets | 1.09 | 1.05 | 1.28 | 1.23 | 1.19 | 1.09 | 1.04 | 1.00 | 0.96 | 0.91 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.21 | 0.17 | 0.15 | - | 0.12 | 0.11 | 0.10 | - |
| Inventory turnover | 1.25 | - | 0.82 | 0.97 | 0.85 | - | - | - | - | - |
| Days sales outstanding | 166d | - | 159d | 205d | 207d | - | 169d | 207d | 183d | - |
| Days inventory outstanding | 292d | - | 443d | 378d | 432d | - | - | - | - | - |
| Days payable outstanding | 261d | - | 99d | 201d | 278d | - | - | - | - | - |
| Cash conversion cycle | 197d | - | 504d | 381d | 361d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | 36.8x | - |
| P / S | 40.2x | - | 29.4x | 27.8x | 25.9x | - | 14.7x | 20.0x | 14.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 48.3% | - | 38.5% | 30.9% | 20.8% | - | 33.9% | 29.2% | 30.9% | - |
| Revenue CAGR (3y) | 32.8% | - | 31.2% | 28.6% | 28.4% | - | 26.4% | 24.4% | 28.9% | - |
| Revenue CAGR (5y) | 30.8% | - | 28.9% | 28.5% | 24.7% | - | 25.8% | 26.8% | 35.7% | - |
| Gross profit growth (YoY) | 42.4% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -9.3% | - | 15.6% | -5.8% | -11.4% | - | -3.3% | 15.9% | 25.6% | - |
| Net income growth (YoY) | -17.8% | - | 13.9% | 2.7% | 17.2% | - | 33.5% | -41.0% | 13.9% | - |
| EPS growth (YoY) | -10.4% | - | 15.9% | 4.8% | 18.1% | - | -20.5% | -25.4% | 27.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -6.0% | - | - | - | -80.4% | - | - | - | 54.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 27.8% | 28.9% | -489.8% | -18838.3% | - | - | - | - | - | 163.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$982.02M totalReportable Segment$982.02M · 100.0%
Product / service
$982.02M totalOncology$683.60M · 69.6%
Biopharma Data$210.13M · 21.4%
Screening$79.73M · 8.1%
Licensing Other$8.56M · 0.9%
Geographic
$982.02M totalUS$923.28M · 94.0%
Non Us$58.74M · 6.0%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Guardant Health against the 5 most active filers in the same SIC group.